amlodipine + candesartan

AD-103 is a fixed-dose combination (FDC) small molecule candidate developed by Addpharma, a South Korean pharmaceutical company specializing in incrementally modified drugs (IMDs). It consists of amlodipine, a dihydropyridine calcium channel blocker (CCB), and candesartan cilexetil, an angiotensin II receptor blocker (ARB). The combination is designed for the treatment of hypertension, leveraging two distinct antihypertensive mechanisms to achieve synergistic blood pressure reduction. Amlodipine acts by inhibiting the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle, leading to peripheral vasodilation. Candesartan cilexetil is a prodrug that is converted to candesartan, which selectively blocks the binding of angiotensin II to the AT1 receptor, thereby inhibiting vasoconstriction and aldosterone secretion. AD-103 is currently in Phase 1 clinical development in South Korea.

Other names

AD-103-Addpharma-CardiovascularAD103-Addpharma-CardiovascularAD 103-Addpharma-Cardiovascular